NGM Bio
2 known investors
NGM Bio develops NGM120, a monoclonal antibody targeting the GDF15/GFRAL pathway, to treat hyperemesis gravidarum and cancer cachexia. The company is running Phase 2 clinical trials for both indications.
2 known investors
NGM Bio develops NGM120, a monoclonal antibody targeting the GDF15/GFRAL pathway, to treat hyperemesis gravidarum and cancer cachexia. The company is running Phase 2 clinical trials for both indications.